GeoVax Set to Unveil Q4 and Full Year 2024 Financial Results with Corporate Update
TL;DR
Investors can gain insights on GeoVax Labs, Inc.'s financial performance and corporate updates during the live conference call.
GeoVax Labs, Inc. will report its 2024 financial results and provide a corporate update during a live conference call at 4:30 PM ET on March 27, 2025.
GeoVax Labs, Inc.'s development of immunotherapies and vaccines aims to combat cancer and infectious diseases, contributing to better global health outcomes.
GeoVax Labs, Inc. will host a live conference call at 4:30 PM ET to discuss financial results, offering a unique opportunity for stakeholders to engage.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, a clinical-stage biotechnology company, will report its fourth quarter and full year 2024 financial results on March 27, 2025, after U.S. market close. The company will follow the financial disclosure with a conference call and webcast at 4:30 p.m. ET, offering investors and stakeholders a comprehensive overview of its recent developments and financial standing.
The company's current focus includes an advanced COVID-19 vaccine program, GEO-CM04S1, which is undergoing multiple Phase 2 clinical trials. These trials are exploring the vaccine's potential for immunocompromised patients, as a booster for chronic lymphocytic leukemia patients, and as a more robust alternative to existing mRNA vaccines.
In addition to its COVID-19 research, GeoVax is advancing its oncology program with Gedeptin®, a novel gene-directed therapy for solid tumors. The company recently completed a Phase 1/2 clinical trial for advanced head and neck cancers and is planning a Phase 2 trial combining Gedeptin® with an immune checkpoint inhibitor.
The upcoming conference call represents an opportunity for GeoVax to demonstrate its progress in developing innovative medical treatments and provide transparency about its financial performance and strategic direction. Investors and healthcare professionals will likely be interested in the company's clinical trial advancements and potential market implications of its research.
Curated from NewMediaWire
